Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||melanoma||sensitive||Vemurafenib||Phase I||Actionable||In a Phase I trial, Zelboraf (vemurafenib) treatment resulted in an overall response rate of 81% (26/32; 2 complete responses, 24 partial responses), and inhibition of tumor Erk and Ccnd1, and reduced cell proliferation in metastatic melanoma patients harboring BRAF V600E (PMID: 20818844; NCT00215605).||20818844|
|BRAF V600E||melanoma||sensitive||Vemurafenib||FDA approved - On Companion Diagnostic||Actionable||In a Phase III trial (BRIM-3) that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival (OS) (13.6 vs 9.7 months, HR=0.81, p=0.03) in patients with BRAF V600E-positive metastatic melanoma, with estimated OS rates of 56%, 30%, 21%, and 17% at 1, 2, 3, and 4 years, respectively (PMID: 28961848, PMID: 21639808; NCT01006980), and BRAF V600E is included on the companion diagnostic (FDA.gov).||28961848 detail... detail... 21639808|
|PubMed Id||Reference Title||Details|
|(21639808)||Improved survival with vemurafenib in melanoma with BRAF V600E mutation.||Full reference...|
|(28961848)||Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.||Full reference...|
|Zelboraf (vemurafenib) FDA Drug Label||Full reference...|
|(20818844)||Inhibition of mutated, activated BRAF in metastatic melanoma.||Full reference...|